Phase 1/ 2 Study of FRF-001, an AAV-9 Gene Therapy, in Patients with FOXG1 Syndrome (FS) Post author: Post published: November 21, 2026 Post category: Continue ReadingPhase 1/ 2 Study of FRF-001, an AAV-9 Gene Therapy, in Patients with FOXG1 Syndrome (FS)
Personalized antisense oligonucleotide therapy for rare pediatric genetic disease: SCN2A Post author: Post published: November 21, 2026 Post category: Continue ReadingPersonalized antisense oligonucleotide therapy for rare pediatric genetic disease: SCN2A
Leveraging iPSCs and a deep learning-based virtual cell model to identify therapeutic targets for ALS Post author: Post published: November 21, 2026 Post category: Continue ReadingLeveraging iPSCs and a deep learning-based virtual cell model to identify therapeutic targets for ALS
Temporal AI models for programming therapeutic cell state transitions Post author: Post published: November 21, 2026 Post category: Continue ReadingTemporal AI models for programming therapeutic cell state transitions
Uncovering disease and cell-type-specific constraints on therapeutic delivery using a human CNS tissue discovery platform Post author: Post published: November 21, 2026 Post category: Continue ReadingUncovering disease and cell-type-specific constraints on therapeutic delivery using a human CNS tissue discovery platform
A precision organoid platform to investigate APOE4 dependent cerebrovascular impairments Post author: Post published: November 21, 2026 Post category: Continue ReadingA precision organoid platform to investigate APOE4 dependent cerebrovascular impairments
Leveraging lessons from normal development to overcome barriers to efficient transplantation of stem cell derived cortical neurons. Post author: Post published: November 21, 2026 Post category: Continue ReadingLeveraging lessons from normal development to overcome barriers to efficient transplantation of stem cell derived cortical neurons.
Allelic Expression States as Determinants of Neurodevelopmental Disorder Risk Post author: Post published: November 21, 2026 Post category: Continue ReadingAllelic Expression States as Determinants of Neurodevelopmental Disorder Risk
Stem Cell-Engineered Off-The-Shelf CAR-NKT Cell Therapy for Multiple Sclerosis Post author: Post published: November 21, 2026 Post category: Continue ReadingStem Cell-Engineered Off-The-Shelf CAR-NKT Cell Therapy for Multiple Sclerosis
Late-stage development of AS-241, an UNC13A Targeting Antisense Oligonucleotide treatment for Amyotrophic Lateral Sclerosis, for IND-enabling studies Post author: Post published: November 21, 2026 Post category: Continue ReadingLate-stage development of AS-241, an UNC13A Targeting Antisense Oligonucleotide treatment for Amyotrophic Lateral Sclerosis, for IND-enabling studies